Gilles Pagès



  • 2016 : President of the French Society of Angiogenesis
  • 2015 : Award Grand Prix Ruban Rose
  • 2013 : Award ARTUR Charity
  • 2013 : Award Novartis on Kidney Cancer
  • 2009 : Award from la Ligue Nationale contre le Cancer


Gilles Pagès has obtained in PhD degree of the University Nice Sophia Antipolis in 1990 and his national degree to direct research (HDR) in 1994.

He is a specialist in molecular biology genetics and cell signaling. Since 1996 his research is dedicated to study the mechanism of normal and pathological angiogenesis in different types of cancers. More recently he has focused his interest on the mechanisms of resistance to targeted therapy in kidney and breast cancers. His is the principal investigator of the team “Norma and pathological angiogenesis” of the Institute for research on cancer and aging of Nice (IRCAN, CNRS UMR 7284/INSERM U 1081).

Dr Gilles Pagès obtained many awards on these topics: Award from la Ligue Nationale contre le Cancer 2009 (8 kE). Award Roche Company 2009 (50 kE); Award ARTUR Charity; Award Novartis on Kidney Cancer 2013. Award Grand Prix Ruban Rose 2015 The last prestigious awards from the Estée Lauder company was dedicated to breast cancers.

Dr. Gilles Pagès team is interested in highly aggressive breast cancers, which overexpress the HER2 receptor, resulting in significant proliferation capacity, associated with increased metastatic properties. At present, the standard treatment, Herceptin, has revolutionized the treatment of these cancers. This targeted therapy allowed spectacular remissions for patients whose prognosis was bleak. However, some patients remain unresponsive to treatment. It is therefore essential to identify these patients to administer alternative treatments. The team of Dr. Gilles Pagès has identified a germinal genetic polymorphism, whose presence is easily identifiable on a blood sample. First identified on tumor cell cultures, this polymorphism was tested on a cohort of 50 patients suffering from HER2 + cancers. It predicted remarkable insensitivity to treatment Herceptin. This polymorphism blocks the expression of tristetraproline protein (TTP) that controls tumor vasculature. Its absence leads the production of blood vessel growth factors and therefore a spread of tumor cells through the circulation blood.

The team's goals are to demonstrate the predictive role of genetic polymorphism in TTP. The team generated antibodies directed against cytokines, inducing exacerbated vascularization following the loss of TTP. These antibodies could therefore constitute a new breast cancer treatment for breast canecrs resistant to the current Herceptin treatment.